Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 4, 1996, Pages 305-316

  Bellamy, William T ^a   Mendibles, Pamela ^a   Bontje, Petra ^b   Thompson, Floyd ^a   Richter, Lynne ^a   Weinstein, Ronald S ^a   Grogan, Thomas M ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Multidrug resistance; Multiple myeloma; SCID mouse

Indexed keywords

ALKYLATING AGENT; AMSACRINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; RADIOISOTOPE; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ANIMAL MODEL; ARTICLE; BONE LESION; CANCER CELL CULTURE; CANCER GRAFT; CANCER GROWTH; CELL CYCLE; CELL CYCLE S PHASE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACCUMULATION; FEMALE; HUMAN; HUMAN CELL; IRRADIATION; MALE; MOUSE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NONHUMAN; OSTEOLYSIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; SCID MOUSE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KARYOTYPING; MICE; MICE, SCID; MULTIPLE MYELOMA; PHENOTYPE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030069665     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050390     Document Type: Article

References (41)

1. Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86-89
2. Azar HA (1975) Experimental plasmacytomas in relation to human multiple myeloma. Ann Clin Lab Sci 4: 157-163
3. Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310: 1353-1356
4. Barlogie B, Epstein J, Selvanayagam P, Alexanian R (1989) Plasma cell myeloma new biological insights and advances in therapy. Blood 73:865-879
5. Bellamy W, Dalton W (1994) Multidrug resistance in the laboratory and clinic. Adv Clin Chem 31:1-61
6. Bellamy WT, Dalton WS, Kailey JM, Gleason MC, McCloskey TM, Dorr RT, Alberts D (1988) Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res 48:6365-6370
7. Bellamy WT, Odeleye A, Finley P, Huizenga E, Dalton W, Weinstein R, Hersh E, Grogan T (1993) An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. Am J Pathol 142:691-698
8. Bellamy W, Odeleye A, Finley P, Huizenga B, Weinstein R, Grogan T (1993) An in vivo model of chemosensitization of multidrug resistant human myeloma cell line in SCID mice. Proc Am Assoc Cancer Res 34:319
9. Bellamy W, Peng Y, Odeleye A, Huizenga E, Xu M, Grogan T, Weinstein R (1994) The addition of cyclosporin A results in markedly elevated tissue levels of doxorubicin in the SCID mouse. Proc Am Assoc Cancer Res 35:354
10. Bergsagel DE (1989) Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma? Eur J Cancer Clin Oncol 25:159-161
11. Burk KH, Drewinko B, Turjillo JM, Ahearn MJ (1978) Establishment of a human plasma cell line in vitro. Cancer Res 38:2508-2513
12. Camba L, Durie BG (1992) Multiple myeloma. New treatment options. Drugs 44: 170-181
13. Carmichael J, DeGraff W, Gazdar A, Minna J, Mitchell J (1987) Evaluation of a tetrazolium-based semi-automatic colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936-942
14. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294-5299
15. Cole SP, Bhardwaj G, Gerlach JH, Mackie J, Grant CE, Almquist KC, Stewart AJ, Kruz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654
16. Colombo T, Zucchetti M, D'Incalci M (1993) Cyclosporin A induces drastic modifications in doxorubicin distribution in mice. Proc Am Assoc Cancer Res 34:322
17. Croese JW, Vas Nunes CM, Radl J, van den Enden-Vieveen MHM, Brondijk RJ, Boersma WJA (1987) The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. Br J Cancer 56:555-560
18. Dalton WS, Grogan TM, Meltzer PS, Scheper R, Durie B, Taylor C, Miller T, Salmon S (1989) Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415-424
19. Dalton WS, Grogan TM, Rybski JA, Scheper R, Richter L, Kailey J, Broxterman H, Pinedo H, Salmon S (1989) Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 73:747-752
20. Dalton WS, Grogan TM, Miller TP (1991) The role of P-glycoprotein in drug-resistant hematologic malignancies. Cancer Treat Res 57:187-208
21. Drewinko B, Mars W, Stragand JJ, Henderson DD, Latreille J, Barlogic B, Trujillo JM (1984) ARH-77, an established human IgG-producing myeloma cell line. II. Growth kinetics, clonogenic capacity, chalone production, xenogeneic transplantations, and response to melphalan. Cancer 54:1893-1903
22. Epstein J, Xiao HQ, Oba BK (1989) P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 74:913-917
23. Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, DeAngelis C, Bunting P (1993) Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res; 53:4837-4842
24. Feinberg AP, Vogelstein B (1983) A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132:6-13
25. Fidler I (1990) Critical factors in the biology of human cancer metastasis. Cancer Res 50:6130-6138
26. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715
27. Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L, Pindur J, Cline A, Scheper R, Tsuruo T, Salmon S (1990) Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 63:815-824
28. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein R, Scheper R (1993) P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 81:490-495
29. Huang Y-W, Richardson JA, Tong AW, Zhang B-Q, Stone MJ, Vitetta ES (1993) Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res 53:1392-1396
30. ISCN (1985) An International System for Human Cytogenetic Nomenclature. Cytogenet Cell Genet 21:1-117
31. Kerr DJ, Graham J, Cummings J, Morrison JG, Thompson GG, Brodie MJ, Kaye SB (1986) The effect of verapamil on the pharmacokinctics of adriamycin. Cancer Chemother Pharmacol 18:239-242
32. Krishan A (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining J Cell Biol 66:188-193
33. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635-1642
34. Potter M, Boyce CR (1962) Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature 193:1086-1087
35. Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MHM, de Leeuw AM (1988) Animal model of human disease multiple myeloma. Am J Pathol 132:593-597
36. Salmon SE, Cassady JR (1993) Plasma cell neoplasms. In: De-Vita V, Hellman S, Rosenberg S (eds) Cancer: principles and practice of oncology, 4th edn. Lippincott, New York, pp 1984-2025
37. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lenhert M, Roe DJ, Miller TP (1991) Multidrug resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78:44-50
38. Thompson FH (1991) Cytogenetic methodological approaches and findings in human solid tumors. In: Barch M (ed) The A.C.T. Cytogenetics Laboratory Manual. 2nd edn. Raven Press, New York, pp 451-488
39. Togo S, Shimada H, Kubota T, Moossa AR, Hoffman RM (1995) Host organ specificity determines cancer progression. Cancer Res 55:681-684
40. Trent JM, Thompson FH (1987) Methods for chromosome Banding of human and experimental tumors in vitro. In: Gottesman MM (ed) Methods in Enzymology. Molecular genetics of mammalian cells. Vol. 151. Academic Press, San Diego, pp. 267-279
41. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I (1987) The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 262: 505-508